HIV Dementia Clinical Trial
Official title:
Exploring Racial Disparities in Sleep Health and Neurocognitive Function in Older Adults With HIV
Despite longer life expectancies due to combination antiretroviral therapy (cART), the prevalence of HIV-associated neurocognitive disorders (HAND) persists thus affecting 52% of the HIV population. Poor sleep quality is commonly reported in older adults and has been related to neurocognitive impairments. This is concerning given studies have shown that up to 75% of adults with HIV experience poor sleep, and by 2020, 70% of adults with HIV will be age 50 and older. It is important to examine sleep quality as it relates to neurocognitive function and HAND in older adults with HIV given its negative impact on cART adherence. Compared to Whites with HIV, African Americans (AA) are disproportionately affected by HIV and are more likely to experience poor sleep quality. This primary goal of this 1-year cross-sectional study is to examine racial differences in sleep quality and neurocognitive function among 60 African Americans and Whites with HIV (age 50+).
This study is designed with two aims: Aim 1a: To explore differences in sleep health between older HIV+ AA and Whites. 1b: To explore differences in domain-specific neurocognitive impairments between older HIV+ AA and Whites. Aim 2a: To explore the relationship between sleep health and neurocognitive function. 2b: To explore the relationship between sleep health and cART adherence. 2c: To explore mediation effects of cART adherence between sleep health and neurocognitive function. This is the first study to explore racial disparities in sleep health and neurocognitive function, using EEG/ERP metrics, among older HIV+ adults. There are two phases in this study: Phase I which consists of neurocognitive testing and sleep assessments with actigraphy, and Phase II which consist of a 20-30 min EEG. Measurements of electrical brain activity will be captured while participants engage in an Attention Network Test which measures executive function, attention, and speed of processing. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01263938 -
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
|
Phase 4 | |
Recruiting |
NCT01599975 -
A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
|
Phase 3 | |
Recruiting |
NCT05586581 -
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05571761 -
Teleneuropsychological Intervention in Asymptomatic HIV Seropositive Patients: N&C NeuroChange
|
N/A | |
Completed |
NCT01665846 -
Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders
|
Phase 1 | |
Completed |
NCT01600170 -
Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
|
Phase 4 | |
Terminated |
NCT03081117 -
Intranasal Insulin for the Treatment of HAND
|
Phase 1/Phase 2 |